ALLMedicine™ Hepatorenal Syndrome Center

Nov 9th, 2021 - Scientific background Protein-energy malnutrition (PEM) occurs in 65-90% of patients with chronic liver disease. PEM is caused by various factors including poor dietary intake, loss of appetite, decreased hepatic protein synthesis, malabsorption a...

Nov 4th, 2021 - Cirrhosis-related mortality is underestimated and is increasing; extrahepatic factors may contribute. We examined trends in cirrhosis mortality from 1999-2017 in the United States attributed to liver-related (varices, peritonitis, hepatorenal synd...

Nov 1st, 2021 - This study will test the hypothesis that the syndrome of acute alcoholic hepatitis results from severe inflammation and dysregulated cytokines. Steroid monotherapy is not effective in all patients and this study will utilize compounds that have th...

Oct 18th, 2021 - Since MELD implementation renal impairment in liver transplant (LT) recipients has become of increasing importance. This is the first study evaluating the course of renal function immediately prior to LT as predictor for long-term renal and overal...

Oct 15th, 2021 - Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel plasma biomarker for liver fibrosis, but less is known about its role in portal hypertension. We aimed to evaluate the association between M2BPGi and hepatic venous pressure gradient (...

Nov 9th, 2021 - Scientific background Protein-energy malnutrition (PEM) occurs in 65-90% of patients with chronic liver disease. PEM is caused by various factors including poor dietary intake, loss of appetite, decreased hepatic protein synthesis, malabsorption a...

Nov 1st, 2021 - This study will test the hypothesis that the syndrome of acute alcoholic hepatitis results from severe inflammation and dysregulated cytokines. Steroid monotherapy is not effective in all patients and this study will utilize compounds that have th...

Apr 28th, 2021 - NECTAR consists of patients with ACLF and renal failure with and without receiving transjugular intrahepatic portosystemic shunt (TIPS) at the Department of Internal Medicine I, University of Bonn, Germany and receiving a structured routine evalua...

Jan 27th, 2021 - The incidence of hepatocellular carcinoma (HCC) is increasing over time among the HIV-infected population, and is an increasingly important cause of morbidity and mortality in HIV-infected individuals. Despite effective treatment for HBV and HCV i...

Oct 19th, 2020 - Acute kidney injury is a common perioperative complication following liver transplantation with an incidence of approximately 55%. Due to the complex physiologic derangements present in cirrhotic patients, multiple etiologies and processes may con...

Mar 4th, 2021 - NEW YORK (Reuters Health) - Details of the phase-3 CONFIRM trial show the vasopressin analog terlipressin can reverse the effects of type 1 hepatorenal syndrome (HRS-1), although not without potentially serious side effects. The study, published i...

Jan 17th, 2021 - Axitinib (Inlyta) plus octreotide LAR failed to demonstrate a significant improvement in progression-free survival (PFS) compared with placebo plus octreotide LAR in patients with advanced G1-2 extra-pancreatic neuroendocrine tumors (NETs), accord...

Dec 20th, 2020 - Ghassan Abou-Alfa, MD Treatment with cabozantinib (Cabometyx) improved median overall survival (OS) by 2.2 months compared with placebo for patients with previously treated advanced hepatocellular carcinoma (HCC), according to findings from the p...

Nov 30th, 2020 - The Japanese Ministry of Health, Labor, and Welfare has approved cabozantinib (Cabometyx) for the treatment of patients with unresectable hepatocellular carcinoma (HCC) that has progressed on prior systemic therapy.1 The approval is based on resu...

Jul 16th, 2020 - The US Food and Drug Administration's (FDA's) Cardiovascular and Renal Drugs Advisory Committee narrowly recommended, by an 8-7 vote, that the agency grant marketing approval to terlipressin for the treatment of hepatorenal syndrome type 1, a seve...